IRON

Disc Medicine, Inc.

Pharmaceutical Preparations · SIC 2834CIK 1816736Held by 5 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

—

Net Income FY2025

$(212.0M)

EPS (Basic, as reported)

$-6.01

Net Margin FY2025

—

ROE FY2025

-28.7%

Total Equity

$740.0M

Shares Out

38M

Business description

Disc Medicine, Inc. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2020–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itNet income: (41) → (212)

Fiscal yearFY2020FY2021FY2022⚑FY2023FY2024FY2025

Research & development(28)(49)(33)(69)(97)(171)

Selling, general & administrative———(22)(33)(65)

General & administrative(6)(20)(14)(22)——

Total operating expenses(34)(69)(47)(91)(130)(236)

Operating income(34)(69)(47)(91)(130)(236)

Interest expense(7)(2)—0(1)(4)

Other income (expense), net—(5)1152124

Pre-tax income——(47)(76)(109)(212)

Income tax expense——0000

Net income(41)(72)(47)(76)(109)(212)

EPS — basic—($40.95)($45.05)($3.42)($3.96)($6.01)

EPS — diluted—($40.95)($45.05)($3.42)($3.96)($6.01)

Shares outstanding — basic (M)—11222835

Shares outstanding — diluted (M)—11222835

⚑ Weighted-average shares changed ×22.00 between FY2022 and FY2023 — likely a stock split. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.